Dimerix (ASX:DXB) recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.
The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis (FSGS), a rare disease that attacks the kidney's filtering units, per the filing.
A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.
The biopharmaceutical company expects the blinded interim analysis in August.
Dimerix's shares were up 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。